Industry Trend Analysis - 2018 Will Be Transformative For Migraine Treatment - NOV 2017


BMI View: The approval of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies for migraine prevention will be one of the standout developments in the central nervous system drugs sector in 2018. Novartis and Amgen will be first to market with Aimovig, followed closely by Eli Lilly and Teva Pharmaceutical Industries, and pricing will be a key issue.

Presentations at the 18th Congress of the International Headache Society (IHC 2017), held in Vancouver, Canada, highlighted a major upcoming event in the migraine treatment market: the arrival of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies.

The Migraine Research Foundation estimates US employers lose more than USD13bn each year as a result of 113mn lost workdays due to migraine. A preventive therapy for these patients is a critical unmet medical need, as they have few therapeutic options. Whilst the range of available acute treatments has increased over time, the field of pharmacological migraine prevention has seen few advances in recent years and there is a need for something designed specifically for this use. Patients eligible for migraine prevention are currently under-treated (only 10% to 30% use prophylactic therapy). There is significant dissatisfaction with current treatments, and large numbers are refractory or intolerant to existing treatment options. It has been estimated that there is a potential multi-billion dollar market opportunity for a preventative therapeutic for migraine and potential novel approaches are being developed.

This article is part of our Americas coverage. To access this article subscribe now or sign up for free trial